Activation of the ROCK1 branch of the transforming growth factor-β pathway contributes to rage-dependent acceleration of atherosclerosis in diabetic ApoE-Null mice

Circulation Research

Volumn 106, Issue 6, 2010, Pages 1040-1051

  Bu, De Xiu ^a   Rai, Vivek ^a   Shen, Xiaoping ^a   Rosario, Rosa ^a   Lu, Yan ^a   D'Agati, Vivette ^a   Yan, Shi Fang ^a   Friedman, Richard A ^a   Nuglozeh, Edem ^a   Schmidt, Ann Marie ^a  

^a Columbia University ^*  (United States)

Author keywords

AGE; Atherosclerosis; RAGE

Indexed keywords

APOLIPOPROTEIN E; RHO KINASE; ROCK1 ENZYME; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVATION; FOCAL ADHESION; GENE DELETION; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; AORTA; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; ENZYME ACTIVATION; FOCAL ADHESIONS; GENE EXPRESSION PROFILING; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; MUSCLE, SMOOTH, VASCULAR; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 77950987553     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.109.201103     Document Type: Article

References (38)

1. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Chow WS, Stern D, Schmidt AM. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4: 1025-1031.
2. Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ Jr, Taguchi A, Olson K, Bucciarelli L, Goova M, Hofmann MA, Cataldegirmen G, D'Agati V, Pischetsrieder M, Stern DM, Schmidt AM. Receptor for advanced glycation endproducts mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E null mice. Arterioscler Thromb Vasc Biol. 2001;21:905-910.
3. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashypa Y, Stern DM, Schmidt AM. RAGE blockade stabilizes established atherosclerosis in diabetic apoli-poprotein E null mice. Circulation. 2002;106:2827-2835.
4. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, Jenkins DG, Stein G, Schmidt AM, Yan SF. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis. 2006;185:70-77.
5. Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, Kalea AZ, Lu Y, Rosario RH, Oruganti S, Nikolla Z, Belov D, Lalla E, Ramasamy R, Yan SF, Schmidt AM. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/-mice. J Clin Invest. 2008;118:183-194.
6. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbes JM, Nawroth PP, Bierhaus A, Cooper ME, Jandeleit-Dahm KA. Receptor for advanced glycation endproducts (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes. 2008;57:2461-2469.
7. Kimura K, Ito M, Amano K, Chihara Y, Fukata M, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science. 1996;273:245-248.
8. Mong PY, Petrulio C, Kaufman HL, Wang Q. Activation of Rho kinase by TNF-alpha is required for JNK activation in human pulmonary micro-vascular endothelial cells. J Immunol. 2008;180:550-558.
9. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
10. Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol. 2004;24:399-404.
11. Grainger DJ. TGF-beta and atherosclerosis in man. Cardiovasc Res. 2007;74:213-222.
12. Mallat Z, Tedgui A. The role of transforming growth factor beta in atherosclerosis: novel insights and future perspectives. Curr Opin Lipidol. 2002;13:523-529.
13. Grainiger DJ, Mosedale DE, Metcalfe JC, Bottinger EP. Dietary fat and reduced levels of TGF beta 1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. J Cell Sci. 2000;113:2355-2361.
14. Gojova A, Brun V, Esposito B, Cottrez F, Gourdy P, Ardouin P, Tedgui A, Mallat Z, Groux H. Specific abrogation of transforming growth factor-beta signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood. 2003;102:4052-4058.
15. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamate C, Merval R, Fradelizi D, Tedgui A. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res. 2001;89:930-934.
16. Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, Georgescu C, Romero R. A systems biology approach for pathway level analysis. Genome Res. 2007;17:1537-1545.
17. Miyazono K, Hellman U, Hellman C, Wernstedt C, Heldin CH. Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem. 1998;263:6407-6415.
18. Saharinen J, Hyytiainen M, Taipale J, Keski-Oja J. Latent transforming growth factor beta binding proteins (LTBPs)-structural extracellular matrix proteins for targeting TGF beta action. Cytokine Growth Factor Rev. 1999;10:99-117.
19. Saharinen J, Taipale J, Keski-Oja J. Association of the small latent transforming growth factor-beta with an eight cysteine repeat of its binding protein LTBP-1. EMBO J. 1996;15:245-253.
20. Mallat Z, Gojova A, Sauzeau V, Brun V, Silvestre JS, Esposito B, Merval R, Groux H, Loirand G, Tedgui A. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res. 2003; 93:884-888.
21. Wang HW, Liu PY, Oyama N, Rikitake Y, Kitamoto S, Gitlin J, Liao JK, Boisvert WA. Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDL receptor null mice. FASEB J. 2008;22:3561-3570.
22. Noma K, Rikitake Y, Oyama N, Yan G, Alcaide P, Liu PY, Wang H, Ahl D, Sawada N, Okamoto R, Hiroi Y, Shimizu K, Luscinskas FW, Sun J, Liao JK. ROCK1 mediates leukocyte recruitment and neointima for mation following vascular injury. J Clin Invest. 2008;118:1632-1644.
23. Riessen R, Kearney M, Lawler J, Isner JM. Immunolocalization of thrombospondin-1 in human atherosclerotic and restenotic arteries. Am Heart J. 1998;135:357-364.
24. Lane TF, Iruela-Arispe ML, Sage EH. Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. J Biol Chem. 1992;267:16736-16745.
25. Shimokawa H, Rashid M. Development of Rho kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci. 2007;28:296-302.
26. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL. Smad7 binds to Smurf2 to form E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell. 2000;6:1365-1375.
27. Clements Rt, Minnear FL, Singer HA, Keller RS, Vincent PA. Rho A and Rho-kinase dependent and independent signals mediate TGF-beta induced pulmonary endothelial cytoskeletal reorganization and permeability. Am J Physiol Cell Mol Physiol. 2005;288:L294-L306.
28. Rosman DS, Phukan S, Huang CC, Pasche B. TGFBR1*6A enhances the migration and invasion of MCF-7 breast cancer cells through RhoA activation. Cancer Res. 2008;68:1319-1328.
29. Fujisawa K, Fujita A, Ishizaki T, Saito Y, Narumiya S. Identification of the Rho-binding domain of p160ROCK, a Rho-associated coiled-coil containing protein kinase. J Biol Chem. 1996;271:23022-23028.
30. Ishizaki T, Mackawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe N, Saito Y, Kakizuka A, Morii N, Narumiya S. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 1996;15:1885-1893.
31. Ruiz-Ortega M, Rodriguez Vita J, Sanchez Lopez E, Carvajal G, Egido J. TGF beta signaling in vascular fibrosis. Cardiovasc Res. 2007;74: 196-206.
32. Edlin RS, Tsai S, Yamanouchi D, Wang C, Liu B, Kent KC. Characterization of primary and restenotic atherosclerotic plaque from the suprficial femoral artery: potential role of Smad3 in regulation of SMC proliferation. J Vasc Surg. 2009;49:1289-1295.
33. Ryan ST, Koteliansky VE, Gotwals PJ, Lindner V. Transforming growth factor-beta dependent events in vascular remodeling following arterial injury. J Vasc Res. 2003;40:37-46.
34. Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, Mazzolai L, Hayoz D, Ruffieux J, Rusconi S, Montani JP, Yang Z. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation. 2004;110:3708-3714.
35. Noma K, Goto C, Nishioka K, Jitsuiki D, Umemura T, Jitsuiki D, Nakagawa K, Oshima T, Chayama K, Yoshizumi M, Higashi Y. Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol. 2007;49:698-705.
36. Nohria A, Prsic A, Liu PY, Okamoto R, Creager MA, Selwyn A, Liao JK, Ganz P. Statins inhibit rho kinase activity in patients with atherosclerosis. Atherosclerosis. 2009;205:517-521.
37. Guo X, Wang L, Chen B, Li Q, Wang J, Zhao M, Wu W, Zhu P, Huang X, Huang Q. ERM protein moesin is phosphorylated by advanced gly-cation endproducts and modulates endothelial permeability. Am J Physiol Circ Physiol. 2009;297:H238-H246.
38. Sun L, Ishida T, Yasuda T, Kojima Y, Honjo T, Yamamoto Y, Yamamoto H, Ishibashi S, Hirata K, Hayashi Y. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in nondiabetic LDL receptor-deficient mice. Cardiovasc Res. 2009;82:371-381.